No Data
Medicenna Announces the Launch of a Marketed Public Offering of Securities
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of Its First-in-Class Anti-PD-1 X IL-2 Bifunctional Superkine MDNA113 at AACR 2026
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
Medicenna Therapeutics Names New Chief Medical Officer; Rose 6.5% From Near 52 Week Lows Wednesday